What the Study Found (In Plain English)
Published in The American journal of gastroenterology (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: This analysis of a phase 3 randomized trial evaluated the efficacy of vonoprazan on prespecified end points for nighttime symptoms in patients with nonerosive reflux disease. Key clinical takeaway: Among 772 subjects, the mean percentage of heartburn-free nights at week 4 was 43.3% for placebo vs 59.9% for vonoprazan 10 mg (least squares [LS] mean difference = 16.5%, P < 0.0001) and 56.4% for vonoprazan 20 mg (LS mean difference, 13.1%, P < 0.0001).
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (The American journal of gastroenterology, 2026-08-01; Phase III Randomized Trial; Rigor 88/100): Among 772 subjects, the mean percentage of heartburn-free nights at week 4 was 43.3% for placebo vs 59.9% for vonoprazan 10 mg (least squares [LS] mean difference = 16.5%, P < 0.0001) and 56.4% for vonoprazan 20 mg (LS mean difference, 13.1%, P < 0.0001).
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.